AVROBIO

128 articles with AVROBIO

• 

  Following bluebird's FDA Win, 4 Companies Aim High with New Gene Therapies

  6/13/2022

  BioSpace looks at several companies developing new gene therapies in the wake of the FDA recommending two of bluebird bio’s lentiviral vector gene therapies.

• AVROBIO Announces Preclinical Gene Therapy Data for Pompe Disease at American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

  5/18/2022

  AVROBIO, Inc. today announced preclinical data demonstrating the efficacy and safety of AVR-RD-03 gene therapy in a mouse model of infantile onset Pompe disease.

• AVROBIO Reports Positive Data From Phase 1/2 Clinical Trial of Investigational Gene Therapy for Cystinosis, Including New Interim Data on Neurocognitive Measures

  5/17/2022

  AVROBIO, Inc. today reported new interim data, including on new visual motor integration, motor coordination and visual perception measures, from a collaborator-sponsored, ongoing Phase 1/2 gene therapy clinical triali of AVR-RD-04.

• 

  With Promising Data, AVROBIO Plans Next Trial for Cystinosis Gene Therapy

  5/17/2022

  Avrobio presented clinical data on Tuesday at the 25th Annual Meeting of the American Society for Gene and Cell Therapy (ASGCT) from its trial of AVR-RD-04, and preliminary results are promising.

• AVROBIO to Present at the H.C. Wainwright Global Investment Conference

  5/16/2022

  AVROBIO, Inc . (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a shared purpose to free people from a lifetime of genetic disease, today announced members of its senior management team will be presenting virtually at the H.C. Wainwright Global Investment Conference, May 23-25, 2022.

• AVROBIO Reports First Quarter 2022 Financial Results and Provides Business Update

  5/10/2022

  AVROBIO Reports First Quarter 2022 Financial Results and Provides Business Update.

• AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - May 06, 2022

  5/6/2022

  AVROBIO, Inc. announced that the company has granted a non-statutory stock option for the purchase of up to 63,000 shares of the company’s common stock to one new employee as an inducement award under the company’s 2019 Inducement Plan.

• AVROBIO to Present New Clinical and Preclinical Data at the ASGCT 25th Annual Meeting

  5/3/2022

  AVROBIO to Present New Clinical and Preclinical Data at the ASGCT 25th Annual Meeting.

• AVROBIO Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Apr 06, 2022

  4/6/2022

  AVROBIO, Inc. announced that the company has granted a non-statutory stock option for the purchase of up to 22,000 shares of the company’s common stock to one employee as an inducement award under the company’s 2019 Inducement Plan.

• AVROBIO to Present at the 21st Annual Needham Virtual Healthcare Conference

  4/5/2022

  AVROBIO to Present at the 21st Annual Needham Virtual Healthcare Conference.

• AVROBIO Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Provides Business Update

  3/17/2022

  AVROBIO, Inc. today reported financial results for the fourth quarter and year ended Dec. 31, 2021, and provided a business update.

• AVROBIO to Present at Two Upcoming Investor Conferences in March

  3/1/2022

  AVROBIO to Present at Two Upcoming Investor Conferences in March.

• AVROBIO Reports Interim Data from Phase 1/2 Clinical Trial of Investigational Gene Therapy for Cystinosis

  2/9/2022

  AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a shared purpose to free people from a lifetime of genetic disease, today reported interim data from a collaborator-sponsored, ongoing Phase 1/2 clinical trial of AVR-RD-04.

• AVROBIO Announces Today Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

  2/4/2022

  AVROBIO, Inc. today announced that the company has granted non-statutory stock options for the purchase of up to an aggregate of 167,000 shares of the company’s common stock to three new employees as inducement awards under the company’s 2019 Inducement Plan.

• AVROBIO Announces the Appointment of Sean O’Bryan as Chief Regulatory Officer

  2/1/2022

  AVROBIO, Inc. today announced the appointment of Sean O’Bryan as chief regulatory officer.

• AVROBIO to Present at Cowen’s 2nd Annual Genetic Medicines Summit

  1/28/2022

  AVROBIO, Inc. announced Azadeh Golipour, Ph.D., chief technology officer at AVROBIO, will present virtually at Cowen’s 2nd Annual Genetic Medicines Summit at 2:00 p.m. ET on Thursday, Feb. 3, 2022.

• AVROBIO to Present New Data from Phase 1/2 Clinical Trial in Cystinosis at WORLDSymposium™ 2022

  1/27/2022

  AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that updated clinical data from its ongoing, collaborator-sponsoredi Phase 1/2 clinical trial in cystinosis will be presented on Feb. 9, 2022, at the 18th Annual WORLDSymposium™ in San Diego, Calif.

• AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Jan 06, 2022

  1/6/2022

  AVROBIO, Inc., a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, announced that the company has granted non-statutory stock options for the purchase of up to an aggregate of 30,500 shares of the company’s common stock to three new employees as inducement awards under the company’s 2019 Inducement Plan.

• AVROBIO Reprioritizes Pipeline Programs

  1/4/2022

  AVROBIO, Inc. today announced that it is shifting its portfolio priorities to focus on other clinical-stage programs and extending its cash runway into the first quarter of 2024.

• 

  AVROBIO Drops Fabry Disease Focus for More Lucrative Pipeline

  1/4/2022

  AVROBIO is switching priorities in 2022 away from its Fabry disease program and into its other more lucrative clinical-stage projects.